



ASX/MEDIA RELEASE

Surgical device sold to US multi-national

- *Reinvestment into further innovative R & D*

Sydney, 29th October 2009 - Global medical technology company, Stryker of the United States, has brought forward completion of the purchase of the Intellectual Property relating to an Australian medical invention used in orthopaedic surgery.

Originally developed, manufactured and commercialised by Sydney-based medical device design and marketing company Advanced Surgical Design and Manufacture (ASDM) (ASX: AMT), the device – The Active Unicompartmental Knee – was marketed in Australia, Europe and Asia under licence to Stryker.

ASDM CEO, Dr Greg Roger explained: “We had recovered our investment in research and development through sales worldwide, but Stryker was keen to take it even further and as a result has brought forward the completion of the contract by 2 years.

“It made sound business sense to strike a deal with Stryker, and the final payment in excess of \$1.0m (over \$3.0m received in total over 3 years) will provide an invaluable injection of funds to be used for on-going R & D at our Sydney manufacturing plant in St Leonards.”

Dr Roger said that ASDM has for 15 years grown to become an innovative designer and marketer of Australian medical and surgical devices, especially in the orthopaedic sector. In more recent years it has expanded into other surgical device areas.

In announcing to the ASX the sale of the IP, Dr Roger also highlighted that the company was now well advanced in trials of its Therapeutic Goods Administration (TGA) approved Australian developed AllVascular Peripheral Access Device (PAD). The PAD allows for more precise targeting of cancer in specific parts of the body, such as the liver or a limb, and has the potential to improve cure rates. Trials are being established in the UK, Germany and Australia.

“We expect results from trials to be available in 2010 and thus commence roll-out of the PAD to the world,” Dr Roger said.

“It’s just over two months ago that we announced to the ASX that ASDM was granted Class IIa approval by the TGA for its medical breakthrough PAD product for use in cancer therapy, which has the potential to save thousands of lives.

“Isolated organ and limb chemotherapy allows the cancer to be subjected to a higher dose of chemotherapy while at the same time reducing the effect of treatment on the rest of the body. It also may allow the use of treatment agents that are not otherwise able to be used due to their toxicity”.



“With huge projected cost savings for the healthcare system, the saving of lives through treatment and the potential upside for ASDM’s income, we are excited about the possibilities for this device. Our long term aim is to see specialist centres in major cities worldwide using ASDM-developed technologies,” concluded Dr Roger.

The PAD allows for multiple uses of balloon catheters or tubes that are inserted into the arteries for treatment. The current method of putting a catheter into an artery requires extensive surgical intervention and is usually only able to be done once or twice for each patient.

The PAD will allow a trial of multiple treatments for each patient using isolated organ perfusion with the potential for improved cure rates.

Media Contact:

ASDM
Dr Greg Roger
Chief Executive Officer
greg.roger@asdm.com.au
Tel: (02) 9439 4448

Media Affairs Pty Ltd
Norman Fay
normanfay@mediaaffairs.com.au
Tel: 0418 99 44 35

About ASDM

ASDM designs and manufactures medical devices. Its principal product is the Active Knee, a prosthetic implant of which more than 5,000 have been implanted. This product is supported by a range of Orthopaedic accessories and surgical tools and other Orthopaedic products.

Since 1994 ASDM has provided a highly effective integrated service to surgeons building on its strengths in design and engineering. Core capabilities that underpin this service are integrated design and engineering, regulatory/compliance competency, manufacturing, distribution and customer service.

The company has built an extensive patent and product development portfolio through collaborative research relationships with universities, companies and surgeon inventors that extends beyond orthopaedics. These collaborations are yielding promising projects in several specialities with strong prospects for commercialisation over the next few years.

For more information, please visit www.asdm.com.au

